REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $399.43 million. The enterprise value is $260.23 million.
Important Dates
The last earnings date was Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 50.12 million shares outstanding. The number of shares has increased by 14.92% in one year.
| Current Share Class | 50.12M |
| Shares Outstanding | 50.12M |
| Shares Change (YoY) | +14.92% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 7.93% |
| Owned by Institutions (%) | 76.14% |
| Float | 41.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.74 |
| Forward PS | 1.74 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.49.
| Current Ratio | 2.93 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.17 |
Financial Efficiency
Return on equity (ROE) is -47.44% and return on invested capital (ROIC) is -20.30%.
| Return on Equity (ROE) | -47.44% |
| Return on Assets (ROA) | -17.56% |
| Return on Invested Capital (ROIC) | -20.30% |
| Return on Capital Employed (ROCE) | -40.96% |
| Revenue Per Employee | $443,960 |
| Profits Per Employee | -$446,711 |
| Employee Count | 353 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.38% in the last 52 weeks. The beta is 1.11, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -48.38% |
| 50-Day Moving Average | 7.37 |
| 200-Day Moving Average | 9.20 |
| Relative Strength Index (RSI) | 50.26 |
| Average Volume (20 Days) | 1,102,610 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, REGENXBIO had revenue of $156.72 million and -$157.69 million in losses. Loss per share was -$3.10.
| Revenue | 156.72M |
| Gross Profit | 124.00M |
| Operating Income | -157.36M |
| Pretax Income | -241.23M |
| Net Income | -157.69M |
| EBITDA | -141.37M |
| EBIT | -157.36M |
| Loss Per Share | -$3.10 |
Full Income StatementBalance Sheet
The company has $267.87 million in cash and $133.53 million in debt, giving a net cash position of $139.20 million or $2.78 per share.
| Cash & Cash Equivalents | 267.87M |
| Total Debt | 133.53M |
| Net Cash | 139.20M |
| Net Cash Per Share | $2.78 |
| Equity (Book Value) | 274.20M |
| Book Value Per Share | 5.47 |
| Working Capital | 206.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$84.04 million and capital expenditures -$2.90 million, giving a free cash flow of -$86.94 million.
| Operating Cash Flow | -84.04M |
| Capital Expenditures | -2.90M |
| Free Cash Flow | -86.94M |
| FCF Per Share | -$1.73 |
Full Cash Flow StatementMargins
Gross margin is 79.12%, with operating and profit margins of -100.41% and -100.62%.
| Gross Margin | 79.12% |
| Operating Margin | -100.41% |
| Pretax Margin | -100.62% |
| Profit Margin | -100.62% |
| EBITDA Margin | -90.20% |
| EBIT Margin | -100.41% |
| FCF Margin | n/a |